Business
Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe
TAVLESSE initial launch in Germany and the U.K. by Grifols S.A. SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:
About this update from Rigel Pharmaceuticals, Inc.
[{"type":"text","content":"TAVLESSE initial launch in Germany and the U.K. by Grifols S.A.\n\n\nSOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Grifols S.A., its collaborative partner in Europe, has launched TAVLESSE® in Germany and the United Kingdom. It was approved by the European Commission in January 2020 for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. TAVLESSE, which is marketed in the U.S. under the brand name TAVALISSE®, is an oral spleen tyrosine kinase (SYK) inhibitor that targets the underlying autoimmune cause of ITP by impeding platelet destruction.\n\"The launch of TAVLESSE in Germany and the United Kingdom is an important step in making our product available to ITP patients across Europe,\" said Raul Rodriguez, Rigel's president and CEO. \"Europe represents approximately half of the estimated $900 million ITP market outside of the U.S., and Grifols's experience with treatments for hematological disorders make them the ideal collaborative partner for our product.\"\nSpain-based Grifols S.A. (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) is a global healthcare company and a leading producer of plasma-derived medicines for the treatment of rare and chronic diseases, including intravenous immunoglobulin (IVIG) which is used in the treatment of ITP.\nAbout ITPIn patients with ITP (immune thrombocytopenia), the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include IVIG, steroids, blood platelet production boosters (TPO-RAs) and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.\nAbout TAVLESSEIndicationTAVLESSE® (Fostamatinib Disodium Hexahydrate) is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.\nTAVLESSE Dosage Fostamatinib dosing requirements must be individualized based on the patient's platel...